71 related articles for article (PubMed ID: 24509410)
1. Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model.
Innes H; Goldberg D; Dusheiko G; Hayes P; Mills PR; Dillon JF; Aspinall E; Barclay ST; Hutchinson SJ
J Hepatol; 2014 Jun; 60(6):1118-26. PubMed ID: 24509410
[TBL] [Abstract][Full Text] [Related]
2. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
3. The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection.
van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Manns MP; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
J Viral Hepat; 2014 Aug; 21(8):568-77. PubMed ID: 24118177
[TBL] [Abstract][Full Text] [Related]
4. Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4.
Saad Y; Ahmed A; Saleh DA; Doss W
Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):920-5. PubMed ID: 23442415
[TBL] [Abstract][Full Text] [Related]
5. Advances in the treatment of hepatitis C.
Lawrence SP
Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
[TBL] [Abstract][Full Text] [Related]
6. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
7. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
8. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes.
Innes HA; McDonald SA; Dillon JF; Allen S; Hayes PC; Goldberg D; Mills PR; Barclay ST; Wilks D; Valerio H; Fox R; Bhattacharyya D; Kennedy N; Morris J; Fraser A; Stanley AJ; Bramley P; Hutchinson SJ
Hepatology; 2015 Aug; 62(2):355-64. PubMed ID: 25716707
[TBL] [Abstract][Full Text] [Related]
9. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
[TBL] [Abstract][Full Text] [Related]
10. Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model.
Petta S; Di Marco V; Bruno S; Enea M; Calvaruso V; Boccaccio V; Rossi S; Craxì A; Cammà C
Liver Int; 2016 Dec; 36(12):1765-1773. PubMed ID: 27164508
[TBL] [Abstract][Full Text] [Related]
11. Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial.
Fartoux L; Degos F; Trépo C; Goria O; Calès P; Tran A; Buffet C; Poynard T; Capron D; Raabe JJ; Roulot D; Naveau S; Grange JD; Poupon RE; Poupon R; Serfaty L
Clin Gastroenterol Hepatol; 2007 Apr; 5(4):502-7. PubMed ID: 17261383
[TBL] [Abstract][Full Text] [Related]
12. Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C.
Yen YH; Kee KM; Chen CH; Hu TH; Lu SN; Wang JH; Hung CH
PLoS One; 2019; 14(1):e0208858. PubMed ID: 30625158
[TBL] [Abstract][Full Text] [Related]
13. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.
Bruno S; Di Marco V; Iavarone M; Roffi L; Crosignani A; Calvaruso V; Aghemo A; Cabibbo G; Viganò M; Boccaccio V; Craxí A; Colombo M; Maisonneuve P
J Hepatol; 2016 Jun; 64(6):1217-23. PubMed ID: 27059129
[TBL] [Abstract][Full Text] [Related]
14. Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy.
Al Marzooqi SH; Feld JJ
Liver Int; 2015 Aug; 35(8):1923-33. PubMed ID: 25939775
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings.
Moorman AC; Rupp LB; Gordon SC; Zhong Y; Xing J; Lu M; Boscarino JA; Schmidt MA; Daida YG; Teshale EH; Spradling PR; Holmberg SD;
Infect Dis Clin North Am; 2018 Jun; 32(2):253-268. PubMed ID: 29778254
[TBL] [Abstract][Full Text] [Related]
16. Kidney transplantation threshold in patients with hepatitis C: a decision analysis model.
Choi G; Lee KG; Wu C; Saab S
Transplantation; 2015 Apr; 99(4):829-34. PubMed ID: 25222014
[TBL] [Abstract][Full Text] [Related]
17. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population.
Innes H; McDonald S; Hayes P; Dillon JF; Allen S; Goldberg D; Mills PR; Barclay ST; Wilks D; Valerio H; Fox R; Bhattacharyya D; Kennedy N; Morris J; Fraser A; Stanley A; Bramley P; Hutchinson SJ
J Hepatol; 2017 Jan; 66(1):19-27. PubMed ID: 27545496
[TBL] [Abstract][Full Text] [Related]
18. Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters.
van der Meer AJ; Hansen BE; Fattovich G; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Manns MP; Ieluzzi D; Zeuzem S; Hofmann WP; de Knegt RJ; Veldt BJ; Janssen HL
Gut; 2015 Feb; 64(2):322-31. PubMed ID: 24815676
[TBL] [Abstract][Full Text] [Related]
19. The disease burden of hepatitis C in Belgium: development of a realistic disease control strategy.
Stärkel P; Vandijck D; Laleman W; Van Damme P; Moreno C; Hindman S; Razavi H; Van Vlierberghe H
Acta Gastroenterol Belg; 2014 Jun; 77(2):280-4. PubMed ID: 25090834
[TBL] [Abstract][Full Text] [Related]
20. Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment.
Mühlbacher AC; Bridges JF; Bethge S; Dintsios CM; Schwalm A; Gerber-Grote A; Nübling M
Eur J Health Econ; 2017 Mar; 18(2):155-165. PubMed ID: 26846922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
